Risk Factors for Oral Mucositis in Children with Cancer
Author Information
Author(s): Fadda Giulia, Campus Guglielmo, Lugliè PierFranca
Primary Institution: Institut Gustave Roussy, Paris, France
Hypothesis
What are the risk indicators for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy?
Conclusion
Patients treated with Busulfan had the highest prevalence of oral mucositis among the different chemotherapy regimens.
Supporting Evidence
- 241 out of 337 children developed oral mucositis during treatment.
- Weight loss was significantly higher in patients with mucositis.
- Busulfan was associated with a higher risk of developing oral mucositis.
Takeaway
This study looked at kids with cancer and found that some types of chemotherapy can cause mouth sores, especially when using a drug called Busulfan.
Methodology
A retrospective cross-sectional case-control study analyzing data from paediatric oncology patients treated with alkylant chemotherapy.
Potential Biases
Potential biases in patient selection and data collection methods.
Limitations
The study is retrospective and may not account for all variables affecting mucositis.
Participant Demographics
Children aged 1 to 15 years, with a higher prevalence of male patients.
Statistical Information
P-Value
p < 0.01
Confidence Interval
95%CI = 1.3–3.0
Statistical Significance
p < 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website